Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

finance.yahoo.com · 2026-08-29

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

TickrTrends take: Axsome Therapeutics operates in a competitive Healthcare sector landscape where direct comparisons to larger players like Amgen are common among investors seeking value opportunities. TickrTrends' current assessment for AXSM remains in an awaiting full valuation status, indicating that comprehensive pricing analysis is still being developed for this name. Investors focused on valuation metrics should monitor for completion of this analysis, as comparative positioning within the Healthcare sector will likely become clearer once full valuation data is finalized.

Read the full story at finance.yahoo.com →